tiprankstipranks
Trending News
More News >
Metropolis Healthcare Ltd. (IN:METROPOLIS)
:METROPOLIS
India Market
Advertisement

Metropolis Healthcare Ltd. (METROPOLIS) AI Stock Analysis

Compare
2 Followers

Top Page

IN:METROPOLIS

Metropolis Healthcare Ltd.

(METROPOLIS)

Rating:64Neutral
Price Target:
₹2,202.00
▲(1.32% Upside)
Metropolis Healthcare Ltd. demonstrates strong financial performance with solid growth and profitability, significantly contributing to its score. Technical analysis indicates bullish momentum but warns of potential overbought conditions. High valuation with an elevated P/E ratio and no dividend yield detracts from the attractiveness, leading to a moderate overall score.

Metropolis Healthcare Ltd. (METROPOLIS) vs. iShares MSCI India ETF (INDA)

Metropolis Healthcare Ltd. Business Overview & Revenue Model

Company DescriptionMetropolis Healthcare Ltd. (METROPOLIS) is a leading diagnostic service provider offering a wide range of clinical laboratory tests and healthcare-related services. Headquartered in India, the company operates numerous laboratories and patient service centers across the country and internationally. Metropolis Healthcare specializes in providing accurate, timely, and reliable diagnostic testing services, catering to hospitals, clinicians, and retail customers. Their services include routine and specialized pathological tests, preventive health check-ups, and wellness packages, leveraging advanced technology and a network of skilled professionals.
How the Company Makes MoneyMetropolis Healthcare Ltd. generates revenue primarily through its extensive network of diagnostic laboratories and patient service centers. The company's main revenue streams include fees charged for various clinical laboratory tests and pathology services. These tests cover a broad spectrum, from routine blood tests and imaging to specialized diagnostics, catering to both walk-in patients and institutional clients such as hospitals and clinics. Additional revenue is derived from preventive healthcare packages and wellness programs aimed at promoting early detection and prevention of diseases. Furthermore, Metropolis may engage in partnerships with healthcare providers, insurance companies, and corporate clients to offer customized health check-up plans, which contribute to its earnings. The company invests in technological advancements and quality assurance to maintain its competitive edge and ensure customer satisfaction, which is crucial for sustaining its revenue growth.

Metropolis Healthcare Ltd. Financial Statement Overview

Summary
Metropolis Healthcare Ltd. exhibits strong financial health across all verticals. Income statement shows robust revenue and profit growth with impressive margins. Balance sheet is solid with low leverage and strong equity base, reducing financial risk. Cash flow is efficient, supporting expansion and shareholder value.
Income Statement
85
Very Positive
Metropolis Healthcare Ltd. shows strong performance with a consistent increase in revenue and profitability. The gross profit margin is impressive at 79.8% for 2025, indicating effective cost management. The net profit margin has also improved, reaching 10.9% in 2025, reflecting enhanced operational efficiency. EBIT and EBITDA margins stand at 55.5% and 22.8% respectively, demonstrating robust profitability. Revenue growth of 10.2% from 2024 to 2025 further underscores the company's solid market position and growth potential.
Balance Sheet
78
Positive
The balance sheet of Metropolis Healthcare Ltd. is strong, supported by a healthy equity ratio of 71.3% in 2025, indicating a solid capital structure. The debt-to-equity ratio is manageable at 0.15, reflecting low leverage and thus reduced financial risk. Return on equity is 10.9%, highlighting efficient use of shareholder funds. Overall, the company maintains a stable and low-risk financial position, which provides a strong foundation for future growth.
Cash Flow
82
Very Positive
Cash flow generation is robust, with a free cash flow growth rate of 9.5% from 2024 to 2025, indicating efficient operations and sound financial health. The operating cash flow to net income ratio is strong at 1.81, showing that the company generates ample cash relative to its profitability. Free cash flow to net income ratio is high at 1.51, demonstrating a solid ability to convert profits into cash. Overall, Metropolis Healthcare Ltd. showcases a strong cash flow profile, facilitating business expansion and shareholder returns.
BreakdownTTMDec 2025Dec 2023Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue13.31B13.31B11.48B12.08B12.28B9.98B
Gross Profit8.52B10.63B8.88B5.81B9.41B7.38B
EBITDA3.10B3.03B3.08B2.97B3.81B3.01B
Net Income1.45B1.45B1.43B1.28B2.14B1.83B
Balance Sheet
Total Assets18.67B18.67B15.02B15.55B15.30B10.04B
Cash, Cash Equivalents and Short-Term Investments1.18B1.18B1.20B1.24B1.81B4.20B
Total Debt2.04B2.04B2.66B1.97B3.79B1.12B
Total Liabilities5.33B5.33B5.11B4.56B6.42B2.96B
Stockholders Equity13.31B13.31B9.88B10.96B8.86B7.07B
Cash Flow
Free Cash Flow0.002.19B1.94B2.00B2.23B2.21B
Operating Cash Flow0.002.63B2.47B2.64B2.53B2.49B
Investing Cash Flow0.00-2.01B467.94M-894.12M-7.38B617.01M
Financing Cash Flow0.00-866.34M-2.92B-1.81B1.63B-326.90M

Metropolis Healthcare Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2173.40
Price Trends
50DMA
1972.91
Positive
100DMA
1826.59
Positive
200DMA
1845.19
Positive
Market Momentum
MACD
59.27
Positive
RSI
61.90
Neutral
STOCH
66.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:METROPOLIS, the sentiment is Positive. The current price of 2173.4 is above the 20-day moving average (MA) of 2118.05, above the 50-day MA of 1972.91, and above the 200-day MA of 1845.19, indicating a bullish trend. The MACD of 59.27 indicates Positive momentum. The RSI at 61.90 is Neutral, neither overbought nor oversold. The STOCH value of 66.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:METROPOLIS.

Metropolis Healthcare Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
70
Outperform
₹274.05B52.46
0.74%10.57%34.11%
69
Neutral
₹68.33B66.28
1.61%21.82%36.97%
68
Neutral
₹107.05B70.53
0.19%22.34%20.71%
64
Neutral
₹111.34B73.61
0.71%12.86%10.42%
63
Neutral
₹25.85B31.99
0.31%13.78%32.21%
61
Neutral
₹93.62B251.62
16.85%-29.52%
51
Neutral
$7.89B-0.33-41.61%2.23%23.26%-2.03%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:METROPOLIS
Metropolis Healthcare Ltd.
2,173.40
46.90
2.21%
IN:HCG
HealthCare Global Enterprises Ltd.
694.05
294.60
73.75%
IN:KRSNAA
Krsnaa Diagnostics Limited
805.30
79.23
10.91%
IN:LALPATHLAB
Dr. Lal PathLabs Limited
3,335.30
-42.00
-1.24%
IN:THYROCARE
Thyrocare Technologies Ltd
1,302.45
453.93
53.50%
IN:VIJAYA
Vijaya Diagnostic Centre Ltd.
1,064.90
164.07
18.21%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 10, 2025